Antimicrobial resistance among gram-negative bacilli causing infections in intensive care unit patients in the United States between 1993 and 2004

Journal of Clinical Microbiology

Volumn 45, Issue 10, 2007, Pages 3352-3359

  Lockhart, Shawn R ^a   Abramson, Murray A ^b   Beekmann, Susan E ^a   Gallagher, Gale ^b   Riedel, Stefan ^a   Diekema, Daniel J ^a   Quinn, John P ^c   Doern, Gary V ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c Jr Hospital of Cook County   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORINASE; CIPROFLOXACIN; ERTAPENEM; GENTAMICIN; IMIPENEM; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TICARCILLIN; TIMENTIN; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD; CITROBACTER FREUNDII; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; INTENSIVE CARE UNIT; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LOWER RESPIRATORY TRACT; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; UNITED STATES; URINE;

CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MICROBIAL SENSITIVITY TESTS; TIME FACTORS; UNITED STATES;

ACINETOBACTER; BACILLI (CLASS); BACILLUS (BACTERIUM); BACTERIA (MICROORGANISMS); CITROBACTER FREUNDII; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA;

EID: 35348832399     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01284-07     Document Type: Article

References (31)

1. Bamberger, D. M., and S. L. Dahl. 1992. Impact of voluntary vs. enforced compliance of third-generation cephalosporin use in a teaching hospital. Arch. Intern. Med. 152:554-557.
2. Clinical and Laboratory Standards Institute. 2006. Performance standards for antimicrobial susceptibility testing; 16th informational supplement document M100-S16. CLSI/NCCLS M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA.
3. Cosgrove, S. E. 2006. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin. Infect. Dis. 42(Suppl. 2):S82-S89.
4. D'Agata, E. M. 2004. Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a 9-year surveillance study. Infect. Control Hosp. Epidemiol. 25:842-846.
5. Diekema, D. J., M. A. Pfaller, R. N. Jones, G. V. Doern, P. L. Winokur, A. C. Gales, H. S. Sader, K. Kugler, and M. Beach. 1999. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin. Infect. Dis. 29:595-607.
6. Empey, K. M., R. P. Rapp, and M. E. Evans. 2002. The effect of an antimicrobial formulary change on hospital resistance patterns. Pharmacotherapy 22:81-87.
7. Fridkin, S. K., H. A. Hill, N. V. Volkova, J. R. Edwards, R. M. Lawton, R. P. Gaynes, J. E. McGowan, Jr., and the Intensive Care Antimicrobial Resistance Epidemiology Project Hospitals. 2002. Temporal changes in prevalence of antimicrobial resistance in 23 U.S. hospitals. Emerg. Infect. Dis. 8:697-701.
8. Friedland, I., L. Stinson, M. Ikaiddi, S. Harm, and G. L. Woods. 2003. Resistance in Enterobacteriaceae: results of a multicenter surveillance study, 1995-2000. Infect. Control Hosp. Epidemiol. 24:607-612.
9. Gales, A. C., R. N. Jones, J. Turnidge, R. Rennie, and R. Ramphal. 2001. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin. Infect. Dis. 32(Suppl. 2):S146-S155.
10. Gaynes, R., J. R. Edwards, and National Nosocomial Infections Surveillance System. 2005. Overview of nosocomial infections caused by gram-negative bacilli. Clin. Infect. Dis. 41:848-854.
11. Goettsch, W., W. van Pelt, N. Nagelkerke, M. G. Hendrix, A. G. Buiting, P. L. Petit, L. J. Sabbe, A. J. van Griethuysen, and A. J. de Neeling. 2000. Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the Netherlands. J. Antimicrob. Chemother. 46:223-228.
12. Ibrahim, E. H., G. Sherman, S. Ward, V. J. Fraser, and M. H. Kollef. 2000. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118:146-155.
13. Itokazu, G. S., J. P. Quinn, C. Bell-Dixon, F. M. Kalian, and R. A. Weinstein. 1996. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin. Infect. Dis. 23:779-784.
14. Jarvis, W. R., J. R. Edwards, D. H. Culver, J. M. Hughes, T. Horan, T. G. Emori, S. Banerjee, J. Tolson, T. Henderson, R. P. Gaynes, et al. 1991 Nosocomial infection rates in adult and pediatric intensive care units in the United States. National Nosocomial Infections Surveillance System. Am. J. Med. 91:185S-191S.
15. Karlowsky, J. A., M. E. Jones, C. Thornsberry, I. R. Friedland, and D. F. Sahm. 2003. Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob. Agents Chemother. 47:1672-1680.
16. Kern, W. V., K. Klose, A. S. Jellen-Ritter, M. Oethinger, J. Bohnert, P. Kern, S. Reuter, H. von Baum, and R. Marre. 2005. Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur. J. Clin. Microbiol. Infect. Dis. 24:111-118.
17. Kollef, M. H., G. Sherman, S. Ward, and V. J. Fraser. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474.
18. Lautenbach, E., B. L. Strom, W. B. Bilker, J. B. Patel, P. H. Edelstein, and N. O. Fishman. 2001. Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Clin. Infect. Dis. 33:1288-1294.
19. Livermore, D. M., D. James, M. Reacher, C. Graham, T. Nichols, P. Stephens, A. P. Johnson, and R. C. George. 2002. Trends in fluoroquinolone (ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg. Infect. Dis. 8:473-478.
20. Neuhauser, M. M., R. A. Weinstein, R. Rydman, L. H. Danziger, G. Karam, and J. P. Quinn. 2003. Antibiotic resistance among gram-negative bacilli in U.S. intensive care units: implications for fluoroquinolone use. JAMA 289: 885-888.
21. NNIS System. 2003. National Nosocomial Infections Surveillance (NNIS) System report, data summary from January 1992 through June 2003, issued August 2003. Am. J. Infect. Control 31:481-498.
22. Paladino, J. A., J. L. Sunderlin, C. S. Price, and J. J. Schentag. 2002. Economic consequences of antimicrobial resistance. Surg. Infect. 3:259-267.
23. Paterson, D. L. 2006. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin. Infect. Dis. 43(Suppl. 2):S43-S48.
24. Pfaller, M. A., R. N. Jones, G. V. Doern, and K. Kugler. 1998. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob. Agents Chemother. 42:1762-1770.
25. Pop-Vicas, A. E., and E. M. D'Agata. 2005. The rising influx of multidrug-resistant gram-negative bacilli into a tertiary care hospital. Clin. Infect. Dis. 40:1792-1798.
26. Raymond, D. P., S. J. Pelletier, T. D. Crabtree, H. L. Evans, T. L. Pruett, and R. G. Sawyer. 2003. Impact of antibiotic-resistant Gram-negative bacilli infections on outcome in hospitalized patients. Crit. Care Med. 31:1035-1041.
27. Rhomberg, P. R., and R. N. Jones. 2007. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005). Diagn. Microbiol. Infect. Dis. 57:207-215.
28. Tumbarello, M., T. Spanu, M. Sanguinetti, R. Citton, E. Montuori, F. Leone, G. Fadda, and R. Cauda. 2006. Bloodstream infections caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob. Agents Chemother. 50:498-504.
29. Unal, S., and J. A. Garcia-Rodriguez. 2005. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004. Diagn. Microbiol. Infect. Dis. 53:265-271.
30. Urban, C., N. Mariano, N. Rahman, A. M. Queenan, D. Montenegro, K. Bush, and J. J. Rahal. 2000. Detection of multiresistant ceftazidime-susceptible Klebsiella pneumoniae isolates lacking TEM-26 after class restriction of cephalosporins. Microb. Drug Resist. 6:297-303.
31. Wisplinghoff, H., M. B. Edmond, M. A. Pfaller, R. N. Jones, R. P. Wenzel, and H. Seifert. 2000. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospitals: clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin. Infect. Dis. 31:690-697.